THE POISON PREVENTION PACKAGING ACT Suzanne Barone, Ph.D. Project Manager for Poison Prevention The views expressed in this presentation are those of the.

Slides:



Advertisements
Similar presentations
Office of New Animal Drug Evaluation Laura L. Hungerford, DVM, MPH, PhD Senior Advisor, Science and Policy, ONADE Professor, University of Maryland School.
Advertisements

What is involved? What are your responsibilities? May 2013: Research Institute, Clinical Research Administration Investigational New Drug Application (IND)
Food Advisory Committee Meeting Risk assessments and susceptible life stages and populations December 16, 2014 Rachel Osterman Associate Chief Counsel,
Successful Solutions Professional Development LLC Chapter 3 Medication Management.
CPSC’s Public Data Base Tom Schroeder 10/11 *This presentation was prepared by CPSC staff. It has not been reviewed or approved by, and may not necessarily.
Consumer Safety and Drug Regulations
“Medication Units” (Opioid Treatment Programs) Drug Enforcement Administration James “Jim” Arnold Chief, Policy Unit Office of Diversion Control D E A.
SOP Melody Lin, Ph.D. Deputy Director, Office for Human Research Protections Director, International Activities Santiago, Chile August.
PTCB Review 3 Calculations Federal Law 1. How many 30-mg tablets of codeine sulfate should be used in preparing the following Rx? Rx: Codeine sulfate15.
Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.
Single Use Expanded Access IND/IDE: FDA and IRB Requirements Before and After Use IRB Webinar October 9,2014.
1 OSHA FEDERAL OCCUPATIONAL SAFETY AND HEALTH ACT (OSHA) OF 1970 George Mason University College of Nursing and Health Science Regulatory Requirements.
What is the Purpose of OSHA?
Nyantee Kpou Consumer Product Safety Commission. Consumer Prod. Safety ActConsumer Prod. Safety Act Federal Hazardous Substances ActFederal Hazardous.
Jack Harrah Governor’s Office of Emergency Services
Introduction to Regulation
Pharmacology Application in Athletic Training Michelle Odai, MS, LAT, ATC, CSCS Florida International University.
FEDERAL REGULATIONS OF MEDICATIONS Food, Drug and Cosmetic Act Protect consumers from adulterated and misbranded foods, drugs, cosmetics, or devices.
Special Topics in IND Regulation
P HARMACY L AWS Pure Food and Drug Act Enacted to stop sale of inaccurately labeled drugs All manufacturers required to put truthful info on labels.
Chapter 6 Dispensing Medications in the Community Pharmacy
U.S. Consumer Product Safety Commission Joseph P. Mohorovic Director IPIA IMPORTANT NOTE: The comments or views expressed are my own and they have not.
Dietary Supplements Bradford W. Williams Special Assistant Division of Dietary Supplement Programs ONPLDS, CFSAN, FDA.
The basics about over-the-counter and prescription drugs. 1 Medicine 101.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 3 Drug Regulation, Development, Names, and Information.
California State Board of Pharmacy Continuing Education Program Senate Bill 151 (Burton)
Special Issues in FDA-Regulated Studies: The Good, the Bad, and the Ugly C. Karen Jeans, MSN, CCRN, CIP COACH Program Analyst VA Office of Research & Development.
Workplace Hazardous Materials Information System (WHMIS)
CPSC Lead Program: Regulations, Guidance, and Outreach Frank J. Nava U.S. Consumer Product Safety Commission January 26, 2006 These comments are those.
1. 2 Melinda Campopiano, MD Medical Officer Center for Substance Abuse Treatment Substance Abuse and Mental Health Services Administration U.S. Department.
Investigational New Drug Application (IND)
Abuse Liability and Drug Scheduling: The Role of the FDA Deborah B
When do I need an IND ? FDA Guidance for Industry – Investigation New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted.
Overview of medication issues and administration of medications in school Adebola E. Orimadegun.
Federal Laws CHAPTER 3. DRUG REGULATION Timeline highlights –Food Drug & Cosmetic (FDC) Act –Durham Humphrey Amendment –Poison Prevention Packaging Act.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
FHSA The FHSA requires precautionary labeling on the immediate container of hazardous household products. The Act also allows the Consumer Product Safety.
Humanitarian Use Devices September 23, 2011 Theodore Stevens, MS, RAC Office of Cellular, Tissue and Gene Therapies Center for Biologics Evaluation and.
Using Medicines Safely (2:50) Click here to launch video Click here to download print activity.
Caring for Research Animals Biomedical Research. Caring for Animals Used in Research Public is concerned with how animals are treated Animals that are.
Be Poison Safe Janet Blair, Child Care Health Consultant Perry County Health Department.
Th/109/1 Packaging of medicine and the safety of our children Experiences with legislation in Germany Brussels Dr. Axel Thiele
Chapter 6 Dispensing Medications in the Community Pharmacy.
PHARMACY LAWS.
Suzanne Sechen, Ph.D. Leader, Ruminant Drugs Team Division of Production Drugs Office of New Animal Drug Evaluation, CVM Labeling Issues.
Pharmacy Laws Poison prevention act of 1970 to reduce accidental poisoning requires most OTC and prescriptions be packaged in child resistant containers.
Jamie Bango Lindsey Croker Kristen Lantz Achidi Ndiforchu.
CPSC AND THE POISON PREVENTION PACKAGING ACT John W. Boja, Ph.D. These comments are those of the CPSC staff, have not been reviewed or approved by, and.
OVER THE COUNTER MEDS INTRODUCTION No prescriptions are necessary and no questions need to be answered to attain these drugs OTC med use saves.
CPSC Data Bases Tom Schroeder 3/11 *This presentation was prepared by CPSC staff. It has not been reviewed or approved by, and may not necessarily reflect.
Regulation of Generic Animal Drugs in the United States
Complaint Handling Medical Device Reporting May 19, 2016 Rita Harden, Director Customer Relations & Regulatory Reporting.
Overview of the CPSC Directorate for Health Sciences * Mary Ann Danello, Ph.D. Associate Executive Director * The views expressed in this presentation.
Storage, Labeling, Controlled Medications Guidance Training CFR § (b)(2)(3)(d)(e) F431.
Review of Testing Protocols May 2016 Lori Mitchell Dixon, PhD President Child Resistant Packaging.
Copyright © 2016, 2013, 2010 by Saunders, an imprint of Elsevier Inc. All rights reserved. Chapter 3 Drug Regulation, Development, Names, and Information.
CLINICAL TRIALS.
Overview of FDA’s Program for Reviewing New Food Contact Substances
Jim Porter, LAT, AT, MA Nevada State Athletic Training Board President
Consumer Product Safety Commission
Drugs and Prescription Records
Drugs and Prescription Records
Using Medicines Safely (2:50)
Learning Objectives Enumerate typical duties of pharmacy technicians with regard to dispensing of over-the-counter and prescription drugs. Explain the.
Presented to the Project Certification Committee on November 16, 2011.
Using Medicines Safely (2:50)
Opening an IND: Investigator Perspective
Ch 18: Pharmacy.
Compounded Drugs and Lack of Premarket FDA-Approval
OSU Controlled Substances Training Module for Researchers
Presentation transcript:

THE POISON PREVENTION PACKAGING ACT Suzanne Barone, Ph.D. Project Manager for Poison Prevention The views expressed in this presentation are those of the CPSC staff, have not been reviewed or approved by, and may not necessarily reflect the views of, the Commission.

CPSC’s Mission l Independent federal regulatory agency that was created in 1972 by Congress in the Consumer Product Safety Act. l “Protect the public against unreasonable risks of injuries and deaths associated with consumer products.” l Jurisdiction over about 15,000 types of consumer products

Acts Under CPSC’s Jurisdiction l Consumer Product Safety Act l Flammable Fabrics Act l Refrigerator Safety Act l Federal Hazardous Substances Act (FHSA) l Poison Prevention Packaging Act (PPPA)

Poison Prevention Packaging Act To protect children from serious personal injury or serious illness resulting from handling, using or ingesting hazardous substances including household chemicals, pharmaceuticals, and cosmetics.

Substances included in 16 CFR § l Ethylene glycol l Fluoride l Furniture polish l Glue removers containing acetonitrile l Hydrocarbons l Kindling and/or illuminating preparations l Methacrylic acid l Methyl alcohol l Mouthwash containing ethanol l Permanent wave neutralizer containing sodium or potassium bromate l Sodium and Potassium hydroxide l Solvents for paint or other coating material l Sulfuric acid l Turpentine

Drugs included in 16 CFR § (a) l acetaminophen l aspirin l controlled drugs l dibucaine l diphenhydramine l ibuprofen l iron-containing drugs and dietary supplements l ketoprofen l lidocaine l loperamide l methyl salicylate l minoxidil l mouthwash l naproxen l oral prescription drugs l OTC-switched drugs

Oral Rx Drug Regulation l 16 C.F.R. § (a)(10) l CR packaging is required for any drug for human use that is in a dosage form intended for oral administration and that is required by Federal law to be dispensed only by or upon an oral or written prescription of a practitioner licensed by law to administer such drug

Clinical Trial Drugs l Oral drugs for human use when they are dispensed during a clinical trial (investigational drugs) for use in the household (outpatient) are regulated under the oral prescription drug regulation because they are dispensed by or at the order of a licensed practitioner.

CR Packaging Exceptions l Not Used In/Around the Household s Institutional Use èHospitals, Nursing Homes s Professional Use

CR Packaging Exceptions (continued) l Rx Drugs s Bulk Drugs to be Repackaged by the Pharmacist s Requested by Patient or Physician s Exempted (16 CFR § 1702) è16 CFR § (a)(10)(i)-(xxi)

CR Packaging Exceptions (continued) l OTCs - Household Products s One size s Labeled (16 CFR §1700.5) è“This Package For Households Without Young Children” è“Package Not Child-Resistant” s Other popular sizes are CR s Imposed exclusive CR s Drain cleaners (16 CFR )

Petitions for Exemption l 16 CFR part 1702 l Requirements - Procedural – 16 CFR § Substantive – 16 CFR §

Petitions for Exemption (Cont.) l Justification – 16 CFR § Lack of toxicity - CR packaging not technically feasible, practicable, or appropriate - CR package is incompatible with substance

Petitions for Exemption (Cont.) l Information and Data Submission - Human experience èChild èAdult - Experimental data - Packaging and labeling èSamples

Examples of Exempted Products l Powdered unflavored aspirin l Effervescent aspirin l Powdered cholestyramine l Oral contraceptives l Hormone replacement therapy l Powdered iron preparations l Effervescent acetaminophen l Hydrocarbon- containing products where the liquid cannot flow freely.

Physician Samples l Oral prescription drugs require special packaging. 16 CFR § (a)(10) l Section 4 of the PPPA grants physicians the authority to order non-CR packaging for their patients in the written prescription.

Special Packaging l “Packaging that is designed or constructed to be significantly difficult for children under five years of age to open or obtain a toxic or harmful amount of substance contained therein within a reasonable time and not difficult for normal adults to use properly..”

Special Packaging l “Nothing in this Act shall authorize the Secretary to prescribe specific packaging designs, product content, package quantity, or with the exception of authority granted in section 4(a)(2) of this Act, labeling.”

Packaging Test Methods l Child Test - 16 FR§ (a)(2) s Panels of 50 children (42-51 months) s Tester restriction - 30% children s Site restriction - 20% children s 5 minute - demo - Teeth - 5 minute s Sequential Pass/Fail Table è16 CFR§ (a)(2)(iii) è80% after 200 children

SEQUENTIAL TEST

Unit Packaging Failure l “A test failure shall be any child who opens or gains access to the number of individual units which constitute the amount that may produce serious personal injury or serious illness, or a child who opens or gains access to more than 8 individual units, whichever is lower, in 10 minutes of testing.”

Determining “F” Serious Injury / Serious Illness l The determination of the amount of a substance that may produce serious personal injury or serious illness shall be based on a 25- pound child.

Toxicological Data l Manufacturers or packagers intending to use unit packaging for a substance requiring special packaging are requested to submit such toxicological data to the CPSC Office of Compliance.

If you have questions about PPPA: l Suzanne Barone l l Geri Smith l l John Boja l l Website:

Packaging Test Methods l Senior Test - 16 FR§ (a)(3) s 100 adults (50-70 years old) s Site restriction (24%) s Tester restriction (35%) s 5 minute/1 minute test period s Screening s 90% Effectiveness

Packaging Test Methods l Metal cans/metal closures and aerosols. èUse 100 Adults aged years èOne 5 minute time period è90% effectiveness